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The remarkable functional diversity of the cell surface
receptor CD44 may be due to expression of multiple
variant isoforms generated by alternative splicing of
variant exons. Functional and correlative data implicate
a role of CD44 variant isoforms in adhesion dependent
processes such as lymphocyte recirculation and tumor
progression and metastasis. We have analyzed 25 primary
cutaneous lymphomas and 35 reactive lymphoid cell
skin infiltrates or T cell-mediated skin diseases for the
expression of CD44 variant isoforms. Irrespective of
histologic typing, staging, and grading, cutaneous
lymphomas as well as nonmalignant skin-infiltrating
CD3FCD4F and CD8F T and CD19F B lymphocytes
exhibited a strong expression of CD44v10 and a moderate
expression of CD44v3 as determined by immunohisto-
CD44 represents a heterogenous class of glycosylatedproteins with molecular masses ranging from 80 to over250 kDa in size. In its most widely expressed 80–90 kDa ‘‘standard or hematopoietic’’ form (CD44s/CD44H), CD44 has been shown to represent the
principle cell surface receptor for hyaluronan (Aruffo et al, 1990;
Miyake et al, 1990; Bartolazzi et al, 1994), and to mediate binding to
laminin, major histocompatibility complex class II invariant chain,
MIP-1β, serglycin, collagen XIV (undulin), and osteopontin/eta-1
(Jalkanen and Jalkanen, 1992; Ishii et al, 1993; Naujokas et al, 1993;
Tanaka et al, 1993; Toyama-Sorimachi et al, 1995; Ehnis et al, 1996;
Weber et al, 1996) with lower affinity. CD44 has been implicated
originally as a lymph node homing receptor, directing lymphocyte
adhesion to high endothelial venules and the extracellular matrix
(Jalkanen et al, 1986), and may also participate in multiple adhesion-
dependent cellular processes such as prothymocyte homing, macrophage
and T cell activation, natural killer cell-mediated cytotoxicity, hemo-
poiesis, and tumor metastasis (Haynes et al, 1989; Underhill, 1992;
Gu¨nthert, 1993; Lesley et al, 1993; Gu¨nthert et al, 1995).
This remarkable functional diversity of CD44 may be due either to
post-translational modifications like glycosylation (Katoh et al, 1995;
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chemistry, immunofluorescence microscopy, and mRNA
analysis. Expression of v5, v6, v7, and v9-containing
CD44 variant isoforms was not detected. Furthermore,
flow cytometry revealed expression of CD44v10 on a
significant proportion of peripheral blood lymphocytes
from Se´zary’s syndrome patients and a remarkable co-
expression with cutaneous lymphocyte antigen. These
results indicate a distinct CD44 variant isoform expression
pattern associated with skin-homing lymphocytes differ-
ent to lymphatic cells at noncutaneous sites. This differen-
tial expression pattern of CD44 variant isoforms may
contribute to the development of lymphocyte skin infilt-
rates and/or the unique biologic behavior of cutaneous
lymphomas. Key words: cutaneous lymphomas/CD4F T cells/
CD8F T cells/skin-homing lymphocytes. J Invest Dermatol
111:464–471, 1998
Lesley et al, 1995), phosphorylation of the cytoplasmic domain (Pure
et al, 1995), and binding of CD44 to the cytoskeleton (Bourguignon
et al, 1993), or to multiple CD44 isoforms generated by alternative
splicing of at least 10 ‘‘variant’’ exons (designated as v1–v10) inserted
into a specific site within a membrane-proximal segment of the
extracellular domain (Screaton et al, 1992). These so-called ‘‘variant’’
isoforms (CD44v) are generated by selective usage of different variant
exons or exon combinations. The subsequently inserted peptide
sequences are remarkably hydrophilic and provide further glycosylation
and chondroitin sulfate attachment sites, which may endow the CD44
molecule with additional binding properties (Bennett et al, 1995b;
Gu¨nthert et al, 1995).
Generation of CD44v isoforms may provide an additional molecular
basis for the functional diversity of the CD44 molecule as indicated
by experimental and correlative data in tumor progression and meta-
stasis. Thus, CD44v isoforms containing variable exon v4–7 or v6–7
have been shown to confer metastatic behavior in a rat pancreas
adenocarcinoma cell line in vivo (Gu¨nthert et al, 1991; Rudy et al,
1993), and lymphogenic spread of this cell line could be prevented by
anti-CD44v6 antibody (Reber et al, 1990; Seiter et al, 1993). Similarly,
transfection of CD44v8–v10 into a murine fibrosarcoma cell line
increased tumor cell growth and metastasis formation (Dougherty et al,
1992), and transfection of CD44v3 into lymphocytic cells resulted in
bone marrow tumor formation in vivo (Bartolazzi et al, 1995). Expression
of some variant exon combinations has been linked to defined tissues
(i.e., CD44v8–v10 to epithelial tissue) (Stamenkovic et al, 1991;
Gu¨nthert, 1993), and in some human malignancies CD44v isoform
expression profiles are correlated with malignant phenotype, tumor
progression, or prognosis (Fox et al, 1993; Gu¨nthert et al, 1995; Zo¨ller,
1995). In a similar fashion, activation as well as infiltrative or aggressive
behavior of lymphocytes or lymphoid neoplasms may be related to
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CD44v isoform expression as suggested by CD44v6 expression during
antigenic stimulation of T lymphocytes (Arch et al, 1992; Koopmann
et al, 1993; Stauder et al, 1995) and correlation of CD44v6 expression
with grading and prognosis in primary nodal non-Hodgkin’s lymphomas
(Koopmann et al, 1993; Ristama¨ki et al, 1995; Stauder et al, 1995).
Infiltration of a specific subset of peripheral blood lymphocytes into
the skin requires a specific multistep process of lymphocyte adhesion to
and migration through vascular endothelium (Butcher, 1991; Springer,
1994; DeGrendele et al, 1996; Uksila et al, 1997). Furthermore, primary
cutaneous lymphomas represent clinicopathologic entities with a bio-
logic behavior significantly different to primary nodal lymphomas
(Willemze et al, 1997). Because adhesion properties of lymphocytes as
well as tumor cell proliferation, growth, and metastasis have been
shown to be determined significantly by the composition of variant
exons spliced into the CD44H frame work (Stamenkovic et al, 1991;
Sy et al, 1991; Dougherty et al, 1992, 1994; Bartolazzi et al, 1995;
Droll et al, 1995; Jackson et al, 1995), the expression pattern of CD44v
isoforms on cutaneous reactive or malignant lymphocytes may not
necessarily correlate with that observed in nodal lymphomas or on
activated peripheral blood lymphocytes. In this study, we provide
evidence that skin-infiltrating lymphocytes lack CD44v6 expression
but strongly upregulate CD44v10 expression during both the manifesta-
tion of an immune response and the development of cutaneous
lymphoid malignancies.
Table I. Clinicohistopathologic features of primary cutaneous
lymphomas
Clinicopathologic classification n Grading Typing Staging
Patch/plaque-stage mycosis fungoides 1 indolent T cell I A
Patch/plaque-stage mycosis fungoides 5 indolent T cell I B
Patch/plaque-stage mycosis fungoides 1 indolent T cell II A
Tumor-stage mycosis fungoides 5 indolent T cell II B
Erythroderma-stage mycosis fungoides 1 indolent T cell III
Large cell anaplastic (CD301) TCL 2 indolent T cell II B
Large cell anaplastic (CD301) TCL 1 indolent T cell IV A
Lymphomatoid papulosis 3 indolent T cell
Subcutaneous panniculitis-like TCL 1 aggressive T cell II B
Se´zary’s syndrome 2 aggressive T cell IV A
Large cell pleomorphic (CD30–) TCL 1 aggressive T cell II B
Immunocytoma 1 indolent B cell II B
Immunocytoma 1 indolent B cell IV B
Table II. Expression of CD44v on lymphocytes within various tissue samples
Lymphocytes within n s v3 v5 v6 v7 v9 v10
Primary cutaneous lymphomas
Patch/plaque-stage mycosis fungoides 7 111a 11 – – – – 111
Tumor-stage mycosis fungoides 5 111 11 – – – – 111
Erythroderma-stage mycosis fungoides 1 111 11 – – – – 111
Large cell anaplastic (CD301) TCL 3 111 11 – – – – 111
Large cell pleomorphic (CD30–) TCL 1 111 11 – – – – 111
Subcutaneous panniculitis-like TCL 1 111 11 – – – – 111
Lymphomatoid papulosis 3 111 11 – – – – 111
Immunocytoma 2 111 11 – – – – 111
Se´zary’s syndrome 2 111 11 – – – – 111
Pseudolymphoma 1 111 11 – – – – 111
Allergic contact dermatitis 7 111 11 – – – – 111
Atopic dermatitis 3 111 11 – – – – 111
Psoriasis vulgaris 4 111 11 – – – – 111
Lichen planus 3 111 (1) – – – – 11
Alopecia areata 2 111 (1) – – – – 11
Toxic epidermal necrolysis 4 111 1 – – – – 111
Pityriasis lichenoides et varioliformis acuta 1 111 (1) – – – – 11
Granuloma anulare 2 111 (1) – – – – 11
Dermatitis herpetiformis 1 111 1 – – – – 111
Lupus erythematodes 4 111 1 – – – – 111
Malignant melanoma 3 111 (1) – – – – 11
Lymph node, inflammatory skin draining 2 111 11 – (1) – – 111
a–, negative; (1), very weak/equivocal; 1 , weak; 11, moderate; 111, strong immunostaining.
MATERIALS AND METHODS
Preparation of tissues and blood samples Human tissue specimens repre-
sented 25 primary cutaneous lymphomas (CL; including two cases of Se´zary’s
syndrome with respective lymph node samples), 10 lymphocyte skin infiltrates
of atopic dermatitis and allergic contact dermatitis, respectively, 25 tissue samples
of diverse reactive or T cell-mediated cutaneous inflammatory diseases, including
a pseudolymphoma, and two cases of inflammatory skin-draining lymph nodes
(Tables I and II). Extirpated samples were halved, one part being immediately
frozen in liquid nitrogen for immunohistochemical staining and RNA extraction.
The other part was fixed in 10% buffered formalin (pH 7.0) and embedded in
paraffin wax for histologic examination. Diagnosis was made independently by
two of the authors according to standard histologic criteria (Willemze et al,
1997), and confirmed by immunophenotyping (CL) and intralocus T cell
receptor γ rearrangement analysis [T cell lymphoma (TCL)].
Peripheral blood mononuclear cells were isolated from whole blood by Ficoll-
Hypaque density centrifugation. T cell enriched populations were obtained from
peripheral blood mononuclear cells by passage through a nylon wool column
(Wako, Neuss, Germany). The proportion of residual CD141 monocytes and
CD191 B cells was ,1%.
Immunohistochemistry, double labeling immunofluorescence micro-
scopy, and flow cytometry Immunohistochemistry was performed as
described previously (Heider et al, 1993; Koopmann et al, 1993). Briefly, 8 µm
cryosections were fixed in acetone for 10 min, washed in phosphate-buffered
saline, and preincubated with normal goat serum (10% in phosphate-buffered
saline). After incubation with the primary antibody for 1 h, immunoreaction
was visualized by APAAP staining (Cordell et al, 1984). All primary antibodies
were titrated to give optimal results. Immunostaining of human skin keratino-
cytes, which express variant exon sequences v2–v10 (Hudson et al, 1995),
served as internal quality standard. Negative controls included omission of the
first, second, and/or third antibody layer and substitution of the primary
antibody by rabbit preimmune or nonimmune IgG or monoclonal mouse IgG
of irrelevant specificity. Primary antibodies included variant exon-specific
monoclonal BBA11 (R&D Systems, Wiesbaden, Germany) directed against v3,
VFF8 (v5), VFF7 (v6), VFF9 (v7), VFF16 (v10), SFF2 directed against CD44
frame work (Bender, Vienna, Austria), and FW11.24 (anti-v9, kindly provided
by U. Gu¨nthert, Basel Institute for Immunology, Basel, Switzerland).
For double labeling immunofluorescence microscopy, cryosections were fixed
in acetone for 10 min at room temperature and blocked with phosphate-
buffered saline containing 1% (wt/vol) bovine serum albumin. Incubation of
tissue sections with monoclonal antibody VFF16 recognized by dichlorotriazinyl
amino fluorescein-conjugated goat anti-mouse IgG (Dianova, Hamburg,
Germany) was followed by incubation with monoclonal mouse antibodies
directed against antigens (clones) CD1a (Na1/34), CD3 (UCHT1), CD4
(MT310), CD8 (DK25), CD16 (DJ130c), CD19 (HD37), and CD68 (KP1)
(DAKO, Hamburg, Germany) detected by biotinylated rabbit anti-mouse
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immunoglobulins (DAKO) and subsequently labeled with streptavidin-Texas
Red (Amersham Buchler, Braunschweig, Germany).
Flow cytometric analyses were performed by one- or two-color immuno-
fluorescence using fluorescein isothiocyanate- and phycoerythrin-conjugated
antibodies. For indirect immunofluorescence, 5 3 105 cells were incubated
with unconjugated primary antibody followed by fluorescein isothiocyanate-
or phycoerythrin-conjugated affinity purified goat anti-mouse IgG F(ab9)2
fragments (Coulter-Immunotech, Hamburg, Germany). Stained cells were
subsequently subjected to flow cytometry on a Coulter Epics XL (Coulter-
Immunotech) and fluorescence emissions collected by selective filtration (530 nm
for fluorescein isothiocyanate, 575 nm for phycoerythrin). Each antibody was
titrated to obtain optimal results, staining with irrelevant appropriate isotype-
matched antibodies served as control. Primary antibodies used were SFF2,
VFF16, and directly fluorescein isothiocyanate-conjugated anti-CLA (cutaneous
lymphocyte-associated antigen/carbohydrated P-selectin glycoprotein ligand-1)
HECA-452 (Pharmingen, San Diego, CA).
Northern blot analysis Total cellular RNA was prepared from tissue
specimens by guanidinium thiocyanate extraction and cesium chloride centrifug-
ation (Chirgwin et al, 1979). RNA samples (10 µg total cellular RNA) were
size fractionated on 1% agarose, 2 M formaldehyde gels and transferred to nylon
membranes by vacuum blotting. Membranes were UV-cross-linked (Stratalinker,
Stratagene, Heidelberg, Germany) and hybridized to random primed [α-32P]
dATP-labeled cDNA probes at 42°C as described (Wagner et al, 1992). After
high stringency washing, finally two times for 60 min in 0.1 3 sodium citrate/
chloride buffer, 0.1% sodium dodecyl sulfate at 55°C for CD44 and 68°C for
β-actin, filters were subjected to autoradiography for 12–48 h. The probe used
comprised nucleotides from position 270–761 of the published human CD44
cDNA sequence (Stamenkovic et al, 1989). The probe was radiolabeled to a
specific activity of 2 3 109 cpm per µg using a T7 DNA polymerase random
priming kit (Stratagene, Heidelberg, Germany).
Semiquantitative reverse transcriptase-polymerase chain reaction (RT-
PCR) Five micrograms total cellular RNA of each case were subjected to
reverse transcription using random hexanucleotide primers and mouse mammary
leukemia virus reverse transcriptase (Promega, Heidelberg, Germany). First
strand cDNA syntheses were carried out for 1.5 h at 42°C in a total volume
of 50 µl. Five microliters of first strand cDNA were amplified by Taq polymerase
(Stratagene, Heidelberg, Germany) essentially as described by Mackay et al
(1994). Oligonucleotide primers used were AAGGAGAAGCTGTGCTACGT-
CG, 59 sequence, and ATCCACACGGAGTACTTGCG, 39 sequence, for β-
actin, and GCACAGACAGAATCCCTGCTACC, 59 sequence, and
GGGGTGGAATGTGTCTTGGTCTC, 39 sequence, according to positions
759–781 and 805–783 (directly flanking CD44 variant exons), respectively, of
the published human CD44 cDNA sequence (Stamenkovic et al, 1989). PCR
reaction parameters were 94°C, 1 min; 55°C, 1 min; 72°C, 1 min over 22
cycles for β-actin. Based on densitometric scanning of β-actin RT-PCR
products, the amount of cDNA for CD44v RT-PCR reaction was adjusted.
PCR reaction parameters for CD44 were 96°C, 5 s; 58°C, 15 s; 72°C, 1 min
over 30 cycles. Under these conditions the increase of PCR products was
confirmed to be linear in both PCR reactions. Furthermore, titration experi-
ments excluded competitive inhibition of generation of large PCR products.
Controls included the omission of reverse transcriptase and the replacement of
cDNA by water in the reverse transcription and the amplification reaction
mixture, respectively. Ten microliter aliquots of the 50 µl reaction were
seperated on a 2.5% agarose gel and the amplification products visualized under
UV-light after staining of the gel with ethidium bromide.
Sequencing of RT-PCR products For sequencing of PCR products, the
amplificates of 251, 197, and 173 base pairs in size were purified by agarose
gel elution (Mermaid Kit, Dianova, Hamburg, Germany). Sequencing of PCR
products was performed directly according to the dideoxy chain termination
method (Sanger et al, 1977) with PCR primers used as sequencing primers.
RESULTS
CD44 standard and variant isoform expression in human
skin Previous studies have indicated strong expression of CD44s in
various human epithelial tissues including the skin and dermal append-
ages (Heider et al, 1993; Mackay et al, 1994; Terpe et al, 1994), whereas
expression of CD44v isoforms has been reported to be restricted to
the epidermis (Heider et al, 1993). By use of variant exon-specific
antibodies we detected intense immunostaining for CD44v3, v5, v6,
v7, v9, and v10 encoding isoforms in the stratum basale and stratum
spinosum of human epidermis, whereas stratum granulosum stained
only sporadically and stratum corneum was consistantly negative (Fig 1).
Stratum basale and stratum spinosum of human epidermis also stained
brightly with CD44s (Fig 1). As described previously (Heider et al,
1993; Mackay et al, 1994) by immunoreaction with blood vessels,
fibroblasts, and connective tissue, CD44s immunostaining of subepider-
mal tissue was different from that observed for CD44v isoforms
(not shown).
Northern blot analysis of different samples from human skin revealed
a consistent pattern of CD44 transcripts. Seven major transcripts were
observed, which according to their size may well represent the 1.6,
2.2, and 5.0 kb species of the hematopoietic isoform, the 2.0, 2.6, and
5.4 kb species of the epithelial isoform, and a variable minor transcript
of 3.6 kb as previously reported for epithelial tumor cell lines (Goldstein
et al, 1989; Harn et al, 1991; Stamenkovic et al, 1991) (Fig 2). By RT-
PCR analysis with variant exon flanking primers a variety of transcripts
with different lengths was observed (Fig 3).
CD44 standard and variant isoform expression on cutaneous
lymphomas Twenty-five primary cutaneous lymphomas including
B and T cell lymphomas of different histologic subtypes, different
grading, and different stages of disease progression (Table I) were
analyzed for CD44v isoform expression. By use of immunohisto-
chemistry, 25 of 25 CL were found to intensely express CD44v10-
and CD44s-encoded epitopes and to moderately express CD44v3. No
immunoreactivity was observed for CD44 variant exons v5, v6, v7,
and v9 (Fig 1, Table II). By double labeling immunofluorescence
microscopy the main proportion of CD44v10-expressing cells could
be identified as CD31CD41 and CD81 T cells or CD191 B cells.
CD161 natural killer cells and some scattered CD681 macrophages
showed a weak CD44v10 immunoreactivity, whereas intraepidermal
CD1a1 dendritic cells and fibroblasts could not be detected to express
CD44v10.
Northern blot analysis of CL revealed the presence of three major
transcripts with a preferential expression of the suggested 5.0 kb species
of hematopoietic transcripts and a weaker expression of the suggested
1.6 and 2.2 species (Stamenkovic et al, 1989) (Fig 2). In subepidermal
tissue-infiltrating CL [including large cell anaplastic (CD301) TCL,
large cell pleomorphic (CD30) TCL, and subcutaneous panniculitis-
like (TCL)] these three transcripts were present almost exclusively.
Comparable results were obtained for epidermal tissue-infiltrating
cutaneous TCL including patch/plaque-, tumor-type, and erythro-
derma-stage mycosis fungoides (Fig 2). These cutaneous TCL charac-
teristically infiltrate the epidermis, thus the presence of the so-called
epithelial 2.0, 2.6, 5.4, and 3.6 kb isoforms in these cases may be due
to contamination with epidermal tissue.
Three major transcripts were also detected by semiquantitative RT-
PCR analysis using primers complementary to variant exons 59 and
39 flanking standard sequences. Subepidermal tissue-infiltrating CL
consistently expressed three transcripts of 251, 197, and 173 base pairs
in size, whereas epidermis-infiltrating cutaneous TCL contained some
additional transcripts at significant reduced amounts corresponding to
those observed in epidermal tissue (Fig 3). Sequence analysis identified
the 251 bp product as complete exon v10 cDNA and the 173 bp
amplificate as complete exon v3. The 197 bp transcript represented a
150 bp splice variant of exon v10. A comparable CD44v10 splice
variant has been previously described in murine tissue (Gu¨nthert, 1993).
CD44 standard and variant isoform expression on reactive
lymphoid cell skin infiltrates of various skin diseases The
uniform and intense expression of CD44v10 and the moderate expres-
sion of CD44v3 in CL, irrespective of histologic subtype, grading, and
stage of disease progression, prompted us to study the expression of
CD44s and CD44v epitopes on reactive lymphocyte skin infiltrates of
atopic dermatitis and allergic contact dermatitis, diverse inflammatory
and T cell-mediated skin diseases, pseudolymphoma, and inflammatory
skin-draining peripheral lymph nodes. By means of immunohisto-
chemistry, northern blot analysis, and RT-PCR sequence analysis, in
10 of 10 reactive lymphocyte skin infiltrates of atopic dermatitis and
allergic contact dermatitis the expression pattern of CD44s and CD44v
isoforms was identical to malignant lymphoid cell skin infiltrates with
high expression levels of v10 and standard epitopes and moderate
expression of CD44v3 (Figs 1–3; Table II). Interestingly, the very
same expression pattern was noted on lymphocytes of diverse inflam-
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Figure 1. Expression of CD44 v10- and v3-containing isoforms on malignant and reactive skin-infiltrating lymphocytes. Tissue samples of tumor-
type mycosis fungoides (A–D) and allergic contact dermatitis (E–H) were stained with anti-CD44v10 (A, E), anti-CD44v3 (B, F), anti-CD44v6 (C, G), and anti-
CD44s (D, H) antibodies. Strong immunoreactivity of lymphocytes with anti-CD44v10 and anti-CD44s antibodies, moderate immunostaining for CD44v3. Note
negative immunostaining with CD44v6-reactive antibody. Cryostat sections, APAAP method. Scale bars: 50 µm.
matory and T cell-mediated skin diseases (Table II). Again, double
labeling immunofluorescence microscopy demonstrated strong
immunostaining for CD44v10 on CD31CD41 and CD81 T cells or
CD191 B cells (Fig 4), weak CD44v10 immunoreactivity on CD161
natural killer cells and some scattered CD681 macrophages, but
no detectable CD44v10 immunoreactivity on intraepidermal CD1a1
dendritic cells and dermal fibroblasts (not shown).
Although normal lymphoid tissue is thought to express CD44s and
to lack CD44 variant isoforms (Heider et al, 1993; Koopmann et al,
1993; Terpe et al, 1994), CD44v6 expression was described upon
antigenic activation (Koopmann et al, 1993). In peripheral lymph node
tissues draining inflammatory skin, however, there was a remarkable
expression of CD44v10 and, to a lesser extent, v3 isoforms identical
to the expression pattern on malignant and reactive lymphocyte skin
infiltrates (Table II).
CD44 standard and variant isoform expression on Se´zary cells
of skin, lymph nodes, and peripheral blood Among the 25 CL
analyzed, two cases of Se´zary’s syndrome were included, from which
skin biopsies, lymph node tissues, and peripheral blood samples were
available. As described already, Se´zary cells infiltrating the skin exhibited
an immunoreactivity pattern as observed in other CL. CD44v10- and
CD44s-encoded epitopes were strongly expressed, whereas only a
moderate immunoreactivity for CD44v3 and lack of staining for CD44
variant exons v5, v6, v7, and v9 could be observed (Fig 5, Table II).
A similar immunostaining pattern was observed on Se´zary cells
involving the respective lymph node tissues. Again, there was a
remarkable expression of CD44v10 and, to a lesser extent, v3 isoforms
identical to the expression pattern observed in Se´zary cells infiltrating
the skin (Fig 5, Table II).
Peripheral blood involvement of Se´zary’s syndrome patients was
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Figure 2. CD44 isoform expression in tissue samples of malignant and
reactive lymphoid cell infiltrates different to normal skin as obtained
by northern blot hybridization. Lanes A, M, N, unaffected skin; lanes B, D,
mycosis fungoides, tumor stage; lanes C, E, mycosis fungoides, patch/plaque
stage; lane F, large-cell anaplastic (CD301) TCL; lanes G, H, mycosis fungoides,
erythroderma stage; lane I, large-cell (CD30–) pleomorphic TCL; lanes J, K,
allergic contact dermatitis; lane L, immunocytoma. Upper panel: 10 µg of
the respective total RNA were analyzed by hybridization with a cDNA
complementary to standard human CD44 cDNA sequences. The migration
positions of 18S rRNA and 28S rRNA are indicated. Note predominant
expression of the 1.6, 2.2, and 5.0 kb hematopoietic isoforms (arrows) in
malignant and reactive lymphoid cell infiltrates as compared with normal skin.
Lower panel: control hybridization with β-actin cDNA probe.
Figure 3. Semiquantitative RT-PCR analysis reveals preferential
expression of distinct CD44v transripts in malignant and reactive
lymphoid cell infiltrates. Lanes 1, 2, large-cell anaplastic (CD301) TCL; lane
3, large-cell (CD30–) pleomorphic TCL; lane 4, mycosis fungoides, erythroderma
stage; lane 5, subcutaneous panniculitis-like TCL; lanes 6–8, mycosis fungoides,
patch/plaque stage; lane 9, immunocytoma; lanes 10–12, mycosis fungoides,
tumor stage; lanes 13–14, normal skin; lane 15, negative control. Quantitation
of cDNA was performed by standardizing for equal amounts of β-actin cDNA.
RT-PCR products were separated on agarose gels. Upper panel: preferential
expression of the 251, 197, and 173 bp CD44v transcripts in malignant and
reactive lymphoid cell infiltrates as compared with unaffected skin. The
additional transcript in lanes 1–4 and 6–12 was identified as the epithelial
isoform of CD44 (v8–v10, due to contamination with epidermal keratinocytes)
by dideoxysequencing. Lower panel: β-actin equilibration of tissue samples. The
mobilities of the molecular weight marker are indicated.
confirmed by cytologic analysis and immunophenotyping of peripheral
blood samples. In contrast to the reported relative lack of CD44v
isoform expression on normal peripheral blood lymphocytes (Pals et al,
1989; Horst et al, 1990; Jalkanen et al, 1991; Joensuu et al, 1993;
Koopmann et al, 1993; Mackay et al, 1994), 19.9% and 29.2%,
respectively, of peripheral blood lymphocytes of Se´zary’s syndrome
patients exhibited immunoreactivity for CD44v10 as determined by
flow cytometry. In both these cases, a significant proportion of
peripheral blood lymphocytes also exhibited expression of CLA (11.9%
and 29.9%, respectively). Two-color flow cytometry revealed that
95.8% and 85.3%, respectively, of CLA-positive lymphocytes coexpres-
sed CD44v10 (Fig 6).
Figure 4. CD3FCD4F and CD8F T lymphocytes and CD19F B
lymphocytes express CD44v10. Double labeling immunofluorescence
microscopy of cryostat tissue sections of a reactive lymphoid cell skin infiltrate
with anti-CD3 (a), anti-CD4 (b), anti-CD19 (c), and anti-CD8 (d) antibodies and
corresponding immunofluorescent staining for CD44v10 (E–H). Streptavidin-
Texas Red-labeling (a–d) and dichlorotriazinyl amino fluorescein-labeling (e–
h) of cryosections. Note CD44v10 immunofluorescence on CD31CD41 and
CD81 T lymphocytes as well as on CD191 B lymphocytes. Scale bar: 25 µm
(a, b, d–f, h), 10 µm (c, g).
DISCUSSION
Peripheral blood lymphocytes are considered to consist of different
subpopulations with tissue selective homing, with one subset repre-
senting skin-associated lymphocytes defined by the expression of CLA/
carbohydrated PSGL-1 (Fuhlbrigge et al, 1997; Picker et al, 1990,
1991). In this study, we have analyzed the expression of CD44v
isoforms on this specialized subset, i.e., reactive and malignant skin-
infiltrating lymphocytes of 25 primary cutaneous malignant lymphomas
and 35 reactive lymphoid cell infiltrates or T cell-mediated skin
diseases. By means of immunohistochemistry and double labeling
immunofluorescence microscopy we could clearly demonstrate that
malignant and reactive skin-infiltrating lymphocytes strongly express
CD44v10-containing isoforms and moderately express CD44v3 con-
taining isoforms. CD44v10 expression was observed predominantly on
lymphatic cells such as CD31CD41 and CD81 T cells as well as
CD191 B cells and to a lesser extent on natural killer cells. Other
CD44v isoforms containing exons v5, v6, v7, and v9 were not
detectable. Because semiquantitative RT-PCR is considered to be a
useful addition to immunohistochemical evaluations (Mackay et al,
1994; Gu¨nthert et al, 1995; Stauder et al, 1995), we additionally
performed CD44v transcript analysis. By use of unaffected skin tissue
samples as control specimens in this RT-PCR approach, as well as in
the northern blot analysis, we could clearly demonstrate CL to exhibit
a different CD44v isoform expression pattern at the mRNA level. By
sequencing of RT-PCR products we could identify the predominantly
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Figure 5. Expression of CD44v10-containing isoforms on skin- and
lymph node-infiltrating Se´zary cells. Tissue samples of Se´zary cells involving
the skin (a) and lymph node tissue (b) were stained with anti-CD44v10 antibody.
Strong and consistent immunoreactivity of Se´zary cells with anti-CD44v10
antibody in both skin and lymph node infiltrates. Cryostat sections, APAAP
method. Scale bar: 50 µm.
expressed mRNA species to represent CD44v10-containing isoforms
constituting of solely exon v10 embedded into the CD44 frame work.
Data presented by Dommann et al (1995), who reported on the
presence of CD44v6 on a small series of CL, are not supported by our
results at the protein or at the mRNA level. Furthermore, neither Orteu
et al nor Bennet et al could demonstrate CD44v6 immunoreactivity in
cutaneous lymphomas and T cell-mediated skin diseases, respectively
(Bennett et al, 1995a; Orteu et al, 1997). The strong staining of the
strata spinosum and basale of normal epidermis and in a small series of
primary nodal non-Hodgkin’s lymphoma (not shown), does also
exclude insufficient immunoreactivity of the CD44v6 antibody used
in this study. Moreover, we established a CD44 cDNA mini-library
from a microdissected primary tissue sample of tumor-stage mycosis
fungoides by cloning of PCR products obtained with primers corres-
ponding to the 59 untranslated region and to the 39 polyA tail of the
CD44 framework sequence. In the meantime, we have sequenced
more than 200 single clones and observed the preferential expression
of CD44s- and v10-containing isoforms. Within these 200 sequenced
clones CD44v6-containing isoforms were not detected (S.N. Wagner
et al, manuscript in preparation).
Se´zary’s syndrome is characterized by the occurrence of neoplastic
T cells (Se´zary cells) in skin, lymph nodes, and peripheral blood. In
this study, we were able to perform CD44v isoform expression studies
on Se´zary cell infiltrates in the skin and lymph nodes as well as in the
peripheral blood compartment of two Se´zary’s syndrome patients.
Again, we observed predominant expression of CD44v10 on Se´zary
cells involving the skin as well as lymph node tissue and found a
significantly increased proportion of CD44v10-expressing lymphocytes
in the peripheral blood of these patients. The lack of CD44v expression
on normal peripheral blood lymphocytes (Pals et al, 1989; Horst et al,
1990; Jalkanen et al, 1991; Joensuu et al, 1993; Koopmann et al, 1993),
on the majority of normal bone marrow cells (Ghaffari et al, 1995), or on
extracutaneous lymphatic tissues (Heider et al, 1993), the predominant
upregulation of CD44v3- and v6-containing isoforms upon activation
of peripheral lymphocytes (Koopmann et al, 1993; Stauder et al, 1995),
and the predominant expression of CD44v3 and v6 in primary nodal
non-Hodgkin’s lymphomas (Koopmann et al, 1993; Ristama¨ki et al,
1995; Stauder et al, 1995), indicate differential CD44v expression on
skin-associated lymphocytes and the majority of activated peripheral
blood lymphocytes/nodal lymphomas. The association of CD44v10
Figure 6. Two color fluorescence analysis. CLA1 T cells from peripheral
blood of Se´zary’s syndrome patients coexpress CD44v10. Both patients exhibited
Se´zary cells . 10% of circulating peripheral blood lymphocytes and an elevated
CD4/CD8 ratio . 5.0.
expression with skin-associated lymphocytes is further supported by
the remarkable coexpression with CLA/carbohydrated PSGL-1, the
so-called skin homing receptor, on peripheral blood lymphocytes of
Se´zary’s syndrome patients.
It has been proposed repeatedly that the multiple isoforms of CD44
are the correlate of a multitude of functions. The upregulated expression
of CD44v10 on CL and reactive lymphocyte infiltrates of the skin
provides an example of distinct and divergent expression of individual
variant exons. Both CD44v3 and v10 constitute exons that may modify
the CD44 molecule post-translationally. Thus, exon v3 contains a
serine-glycine-serine-glycine motif that confers additional ligand bind-
ing specificities to CD44, i.e., a heparan sulfate attachment side, which
can bind and present a number of cytokines (Bennett et al, 1995a).
This may constitute an important contribution to the inflammatory
conditions at the sites of lymphocyte skin infiltrates. The role of this
particular modification in CL, however, remains to be established.
What could be the function of CD44v10 upregulation on skin-
infiltrating lymphocytes? Exon v10 contains a chondroitin sulfate
attachment site that may induce new binding properties. Thus, cell
surface chondroitin sulfate proteoglycans antagonize cell adhesion to
extracellular matrix proteins such as fibronectin, collagen, and laminin
(Knox and Wells, 1979; Rich et al, 1981; Rosenberg et al, 1985;
Yamagata et al, 1989), regulate motility and invasiveness of murine
melanoma cells when attached to CD44 (Faassen et al, 1992), and
mediate binding by other CD44 molecules (Droll et al, 1995). This is
further supported by experimental models using CD44v101 Namalwa
transfectants demonstrating increased homotypic and comparable
heterotypic cell–cell adhesion properties as well as increased invasion
into types I and III collagen matric when compared with CD44s1
transfectants.1 Thus, one may speculate that CD44v10-expressing
malignant and reactive CD31CD41 and CD81 T as well as CD191
B lymphocytes may represent lymphocyte subsets with specific migra-
tion and homing properties. In vivo models of skin infiltration and
lymphocyte activation by appropriately transfected lymphoid cell lines
shall help to elucidate the functional consequences of CD44v10
expression on lymphocytes in more detail.
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